Document:

Exhibit 10.2

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

 

11770 Bernardo Plaza Court, Suite 353

San Diego, CA 92128

Phone: 858-618-1400 Facsimile 858-618-1441

 

Confidential

 

April 26, 2016

 

Dr. Roger Crystal

Chief Executive Officer

Opiant Pharmaceuticals, Inc.

401 Wilshire
Blvd.

12th Floor

Santa Monica,
CA 90401

 

Re: Summary
License Terms

 

Dear Dr.
Crystal:

 

As
we have discussed, we understand that Opiant Pharmaceuticals, Inc. (F/k/A Lightlake Therapeutics,
Inc.) (“Opiant”)
is interested in exploring the possibility of exclusively licensing certain intellectual property
rights of Aegis Therapeutics, LLC (“Aegis”) related to its technology
and intellectual property for certain Products as described more particularly in the enclosed term sheet dated April 26, 2016 attached
as Exhibit 1 (the “Term Sheet”).

 

In the interest
of facilitating the possible transaction, Aegis is willing to grant to Opiant the exclusive right to negotiate such a license pursuant
to Section D.4 of the Amended and Restated Material Transfer, Option and Research License Agreement (the “Agreement”)
as executed on April 26, 2016 and effective as of December 1st, 2014 (the “Research Agreement”) and under the following
terms and conditions:

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

Confidential

 

Opiant Pharmaceuticals, Inc.

Letter Agreement

April 26, 2016

Page 2 of 2

 

Announcements.
Subject to the terms of this section, the parties will not make any public announcement concerning this letter agreement or discussions
relating to a possible transaction between them. Any such disclosures shall be subject to the terms of the Research License and
the Mutual Confidentiality Agreement dated November 13, 2013 between Aegis and Opiant. Notwithstanding the foregoing, either party
shall be free to disclose, without the other party’s prior written consent, any information that was publicly disclosed prior
to the date of this letter agreement, including without the requirement to seek a confidential treatment request of any such information.
To the extent practicable, the disclosing party shall be given advance notice of any legally required disclosure of Confidential
Information by the other party, and the disclosing party shall provide any comments on the proposed disclosure within five (5)
business days. To the extent that either party determines that it or the other party is required to file or register this letter
agreement or information arising from the letter agreement, or a notification thereof to comply with the requirements of an applicable
stock exchange or NASDAQ regulation or any governmental authority, including without limitation the U.S. Securities and Exchange
Commission, the Competition Directorate of the Commission of the European Communities or the U.S. Federal Trade Commission, such
party shall promptly inform the other party thereof. Prior to making any such filing, registration or notification, the parties
shall agree on the provisions of this letter agreement for which the parties shall seek confidential treatment, which provisions
shall be reasonable and in accordance with information that such agency would reasonably agree to redact under a confidential treatment
request, provided that a confidential treatment request will not be required for information previously disclosed. The parties
shall cooperate, each at its own expense, in such filing, registration or notification, including without limitation such confidential
treatment request, and shall execute all documents reasonably required in connection therewith. Notwithstanding the foregoing,
in the event that the disclosing party does not provide comments within the five (5) business day period from notification by the
other party, then the other party shall be free to publicly disclose such confidential information in accordance with the terms
herewith.

 

Expenses. Each party will
pay its own expenses incident to this agreement, any definitive agreement and the transaction proposed by the Term Sheet (whether
or not the transaction is consummated), including counsel fees and accounting fees.

 

Governing Law. This agreement
shall be governed by and construed in accordance with the laws of the State of New York without regard to conflicts of law principles.

 

Please countersign
below to indicate Opiant’s agreement to the matters set forth above. This agreement shall be binding on any acquiror or successor
in interest of either party.

 

	 	Very truly yours,	 
	 	 	 
	 	Aegis Therapeutics, LLC	 
	 	 	 	 
	 	By:	/s/ Ralph R. Barry	 
	 	 	Ralph R. Barry	 
	 	 	Chief Business Officer	 

 

	 	Agreed to as of April 26, 2016	 
	 	Opiant Pharmaceuticals, Inc. 	 
	 	 	 	 
	 	By:	/s/ Dr. Roger Crystal	 
	 	 	Dr. Roger Crystal	 
	 	 	Chief Executive Officer	 

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

Exhibit 1

 

License Agreement Terms and Conditions

 

April 26, 2016

**** = Redacted

 

	License:	
        The license to be granted by Aegis
        Therapeutics, LLC (“Aegis”) to Opiant Pharmaceuticals,
        Inc. (f/k/a Lightlake Therapeutics Inc.) (“Opiant”)
        is a royalty-bearing license under all applicable patent and other proprietary rights of Aegis, including without limitation rights
        under the Technology and Aegis’s interest in the New Inventions and Joint Inventions (collectively, “Aegis IP Rights”)
        to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) the Products
        in the Field in the Territory.

         

        Subject to the Right of First Refusal and
        Option below, Aegis shall not license to any third party, and hereby grants an exclusive option to Opiant to license, the Aegis
        IP Rights to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) naloxone
        for treatment or prevention of opioid overdose (“Opioid Field”) in the Territory.

         

        Notwithstanding the above license to manufacture
        the Excipient, Opiant will covenant and agree to not exercise such right to make or have made Excipient for so long as Aegis remains
        in compliance with the terms of the Supply Agreement. If the Supply Agreement becomes terminated in accordance with its terms,
        or if Opiant exercises its right to terminate Aegis’ exclusive right to supply Excipient, then Opiant may exercise its license
        right to make or have made Excipient, which license right shall automatically extend to any contract manufacturer engaged by Opiant,
        any of its Affiliates and/or any sublicensee to manufacture Excipient.

	 	 
	Excipient:	Aegis’s proprietary chemically synthesizable Excipient(s), including without limitation the Intravail® excipients.
	 	 
	Product(s):	Pharmaceutical formulations containing the Compound as an active ingredient and the Excipient.
	 	 
	Compound:	Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing.
	 	 
	Option Compound	Naltrexone and nalmephene/ nalmefene.

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

	Field:	Treatment or prevention of any disease, disorder, state, condition or malady in humans except in the Opioid Field, provided that upon election of Opiant in writing and payment of the Option Fee, the “Field” shall include the Opioid Field.
	 	 
	 	The Option Fee shall mean one hundred thousand dollars ($100,000) and agreement by Opiant that by expansion of the Field to include Opioid Field, that Products for the Opioid Field in the Territory using the Aegis IP Rights shall be subject to the same monetary obligations as other Products in the Field (i.e. Option Field milestones, royalties under terms and conditions to be negotiated in good faith by the parties).  
	 	 
	Territory:	Worldwide
	 	 
	License Fee:	Opiant shall pay to Aegis a nonrefundable and noncreditable license fee of $300,000 on the effective date of the license agreement.
	 	 
	 	Opiant may elect to pay up to 50% of the License Fee by issuing to Aegis shares of Opiant’s common stock subject to the following:

 

		a.	There must be a public market for Opiant's shares and Opiant must be current with all statutory
filings

 

		b.	The shares shall be issued pursuant to Rule 144 of the Securities Act of 1933;

 

		c.	The number of shares to be issued shall be calculated to 75% of the average closing price for the
previous 20 trading days;

 

		d.	After the statutory holding period has been satisfied, Opiant’s legal counsel shall provide a legal opinion so that the
shares can be sold in accordance with Rule 144 of the Securities Act of 1933.

 

	Milestones:	Opiant will pay to Aegis the following development milestones for the Products:

 

	Milestone	 	Compound	 	 	Each Option

Compound(s) 	 
	Successful completion of the first human study.	 	$	300,000	 	 	$	250,000	 
	Successful completion of the first Phase II	 	$	750,000	 	 	$	500,000	 
	Successful completion of the first Phase III	 	$	1,200,000	 	 	$	1,000,000	 
	Approval of the first NDA or its equivalent	 	$	4,000,000	 	 	$	3,500,000	 

 

	 	Beginning on the first anniversary of the effective date of the license agreement and through the first Product approval by Opiant, Opiant shall be required to make minimum quarterly nonrefundable payments (“Quarterly Payments”) to Aegis in the amount of $25,000. These Quarterly Payments would be fully creditable and treated as a prepayment against future milestones or royalties and are required in order to maintain the license.

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

	 	If, at the time when any milestone payment listed above is due, Opiant has not paid all other milestone payments (if any) previously listed above, then at such time Opiant shall pay all such unpaid milestone payments (other than product approval milestones).  

 

	Right of First Refusal and Option	
        Provided that the license agreement has not been terminated,
during the first two (2) year period beginning on the Effective Date, Aegis grants Opiant a right of first refusal and option
to add any, or all, of the compounds included under Option Compound or the Opioid Field to the license agreement (the “Opiant
Option”). Except as permitted by this section, Aegis shall not sell, license, offer for sale, offer for license or agree
to sell or license any Aegis Technology relating to the Option Compound to any third party during the first two (2) year period
beginning on the Effective Date.

        The following sets forth the procedure whereby Opiant may exercise the Opiant Option.

 

	 	1.	In the event that Aegis is approached by a third party interested in licensing the Option Compound(s) or the Opioid Field, Aegis shall provide a written notice to Opiant specifying the specific compound(s) or the Opioid Field (the “Aegis Notice”).
	 	 	 
	 	2.	
        Opiant shall as soon as possible,
but in no event longer than forty (40) days of receipt of the Aegis Notice, provide a written notice to Aegis whether Opiant intends
to exercise the Opiant Option. In the event that Opiant does not does exercise the Opiant Option or fails to deliver to Aegis
its intent to exercise such option within the forty (40) day period, then Aegis shall be free to grant such licenses to any other
third party covering such Option Compound(s) or the Opioid Field for a period of up to twelve (12) months thereafter (the “Third
Party Negotiation Period”).

	 	 	 
	 	3.	In the event Opiant exercises the Opiant Option, then as partial consideration for the grant to Opiant of the rights under the license agreement for each Option Compound Opiant shall pay to Aegis a nonrefundable and noncreditable license issuance fee of Two-Hundred and Fifty Thousand U.S. dollars (U.S. $250,000). Opiant may elect to pay up to 50% of the Option Fee by issuing to Aegis shares of Opiant’s common stock subject to the procedures for the License Fee payment in the form of Opiant shares. In the event that Opiant exercises the Opiant Option specific to the Opioid Field then Opiant shall pay to Aegis the Option Fee.

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

	 	4.	In the event Opiant does not exercise the Opiant Option and the other interested third party either: (i) does not license within the Third Party Negotiation Period, under either feasibility or commercial licenses, the Option Compound; or (ii) the license pertaining to such Option Compound that has been exclusively licensed has been subsequently terminated, or prior to the end of the Third Party Negotiation Period negotiations with the interested third party licensee are terminated as determined in Aegis’ sole discretion, then Aegis shall within thirty (30) days of such termination provide written notice to Opiant that the Option Compound remains available. Any subsequent inquiry by the same or any other third party interested in licensing such Option Compound shall again be subject to the requirements of this section.
	 	 	 
	 	5.	Without limiting the foregoing right of first refusal, Opiant may in its sole discretion elect to affirmatively exercise the Opiant Option with respect to any available Option Compound at any time by written notice to Aegis, in which case the same license issuance fees specified in subsection 3 shall apply.

 

	Royalties:	During the Royalty Term, Opiant shall pay to Aegis royalties on annual Net Sales of Products, on a country-by-country and Product-by-Product, in an amount equal to the applicable rate set forth in the table below, times the annual Net Sales of Products by Opiant, its sublicensees and their respective Affiliates:

 

	Annual Net Sales (U.S. $)	 	Royalty Rate	 
	Aggregate Annual Net Sales during a Calendar Year less than or equal to Fifty Million Dollars (U.S. $50,000,000)	 	 	2.0	%
	 	 	 	 	 
	Aggregate Annual Net Sales during a Calendar Year greater than Fifty Million Dollars (U.S. $50,000,000) and less than or equal to Two Hundred and Fifty Million Dollars (U.S. $250,000,000)	 	 	3.0	%
	 	 	 	 	 
	Aggregate Annual Net Sales during a Calendar Year greater than Two Hundred and Fifty Million Dollars (U.S. $ 250,000,000 and less than or equal to Five Hundred Million Dollars (U.S. $500,000,000)	 	 	4.0	%
	 	 	 	 	 
	Aggregate Annual Net Sales during a Calendar Year greater than Five Hundred Million Dollars (U.S. 500,000,000) and less than or equal to One Billion Dollars (U.S. 1,000,000,000)	 	 	5.0	%
	 	 	 	 	 
	Aggregate Annual Net Sales during a Calendar Year greater than One Billion Dollars (U.S. 1,000,000,000)	 	 	5.5	%

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

	 	The royalty percentage then applicable to Net Sales of any Product made in any country in the Territory shall be reduced by fifty percent (50%) if at the time of the sale of such Product in such country, the use, manufacture, offer for sale, sale and import of such Product in such county is not covered by a Valid Claim.
	 	 
	 	These royalties will be reduced by up to 50% in any payment period for the costs associated with the license of additional technology by Opiant, its affiliates or sublicensees in order for Opiant to use the Aegis Enhancement Agent for the development or commercialization of the Product but only for sales in the country where the third party patent rights are valid.
	 	 
	 	If the level of competition, patent protection or general commercial environment affects in any material respect the commercial viability of a Product at the then applicable royalty rate due to Aegis from Opiant for any country(ies) within the Territory, upon written request from Opiant, Aegis will negotiate in good faith with Opiant to endeavor to reach mutual agreement on a reduction to such royalty rate for the applicable Product and applicable country(ies).
	 	 
	 	“Royalty Term” shall mean, with respect to a Product in a country, a period which is the longer of: (a) if the manufacture, use or sale of such Product in such country is covered by a Valid Claim, the term for which such Valid Claim remains in effect, and (b) fifteen (15) years from the date of the First Commercial Sale of such Product in such country.
	 	 
	 	“Valid Claim” shall mean, on a country-by-country basis, either (a) a claim of an issued and unexpired patent in any Aegis IP Rights or the Product (excluding any patent owned by Opiant covering solely a Compound), which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, or which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application in any Aegis IP Rights or the Product (excluding any pending patent application owned by Opiant), which claim was filed in good faith and has not been abandoned or finally disallowed without the possibility of appeal or refiling of such application, and in any event has not been pending for more than seven (7) years.

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

	 	“Net Sales” shall mean, with respect to any Product, the invoiced sales price of such Product by Opiant, its sublicensees and their respective Affiliates billed to independent customers who are not Affiliates, less (a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such independent customers for spoiled, damaged, outdated, rejected or returned Product; (b) actual freight and insurance costs incurred in transporting such Product to such customers; (c) cash, quantity and trade discounts and other price reductions; (d) sales, use, value-added and other direct taxes incurred; and (e) customs duties, surcharges and other governmental charges incurred in connection with the exportation or importation of such Product. Sales between or among Opiant and its Affiliates or sublicensees shall be excluded from the computation of Net Sales except where such Affiliates or sublicensees are end users of the Product, but Net Sales shall include the subsequent final sales to third parties by such Affiliates or sublicensees.
	 	 
	Maximum Reductions: 	Notwithstanding anything other to the contrary, the provisions which allow for a reduction, credit or offset from the regularly scheduled payment rate or amount (e.g., royalties and milestone payments) shall not be used cumulatively to result in more than a fifty percent (50%) reduction in the regularly scheduled payment; but any unused reduction, credit or offset, as a result of this fifty percent (50%) floor, may be carried forward and used subsequently in the future as a reduction, credit or offset against a later accruing payment obligation, but still subject to the same fifty percent (50%) floor as set forth above. 
	 	 
	Disclosure of Technology:	Aegis will cooperate with Opiant in the disclosure of any Aegis technology or know-how that would aid Opiant in the development or manufacture of the Products.
	 	 
	Right to Sublicense:	Opiant shall have the right to grant sublicenses to third parties without the prior consent of Aegis. Any sublicense granted by Opiant shall be consistent with Opiant’ obligations under the license agreement with Aegis. At Opiant’s option Aegis will accept a percentage, to be negotiated in good faith by the Parties, of any sublicense revenue received by Opiant to avoid royalty stacking issues.
	 	 
	Intellectual Property	It is the intent of the Parties that Aegis shall own all rights to the Aegis Intravail® Technology and the Aegis Know-how. Aegis shall also own any improvements to the Aegis Intravail® Technology or the Aegis Know-how that may be developed by Opiant. Aegis shall be free to license its own technology, including any Opiant improvements, to others on such terms and conditions as it sees fit. Aegis’ rights shall only be limited by the License granted under the license agreement and as described above regarding commercialization of a Product.

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

	 	Ownership of Intellectual Property: Notwithstanding United States laws regarding inventorship, the Parties agree any patentable new inventions, innovations, developments or discoveries resulting from the activities under the license agreement (“New Inventions”) regardless of whether any such New Inventions are made solely by a party or jointly by both parties, and all patent and other intellectual property rights in any of the New Inventions, shall be owned as follows:
	 	 
	 	(a)  Opiant shall remain the sole owner of all rights in the Compound, the Opiant Know-how and all existing patents and patent applications relating to the use of such technology.
	 	 
	 	(b)  Aegis shall remain the sole owner of all rights in the Aegis Intravail® Technology, the Aegis Know-how and all existing patents and patent applications relating to the use of such technology.
	 	 
	 	(c)  All New Inventions covering Products, including without limitation any invention relating to the use of the Aegis Intravail® Technology or the Aegis Know-how that are invented in whole or in part by Opiant (a “Joint Invention”), regardless of whether it may be commercially useful, shall be owned solely by Aegis. Nothing herein shall affect the right of Opiant to invent and seek intellectual property protection for inventions that do not comprise Aegis Intravail® Technology.
	 	 
	 	(d)  Nothing herein shall affect the ability of Aegis to develop and license intellectual property relating to Aegis Intravail® Technology or any New Invention that is not a Joint Invention.
	 	 
	 	(e)  In the event a patent application on a New Invention includes at least one claim incorporating limitations that comprise Aegis Intravail® Technology, the New Invention shall be considered a Joint Invention.
	 	 
	Patent Costs 	Subsequent to the effective date of the license agreement, Opiant shall reimburse Aegis for actual costs incurred by Aegis under the Aegis Patent Rights that are specific only to the Compound(s) and/or Product(s) including but not limited to all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such patents and patent applications.
	 	 
	Due Diligence and Rights Reversion	
        The definitive license agreement shall include mutually
agreed upon due diligence obligations for the development and commercialization of the Product.

        In the event Opiant does not pursue Commercially
        Reasonable Efforts to Exploit a Product, then Aegis will have the right to terminate the license granted, whereupon Opiant shall
        assign and transfer exclusively to Aegis (even as to Opiant) all data and intellectual property that relates solely to such Product,
        at Aegis’ expense. Said termination will occur upon Aegis delivering to Opiant a written notice of termination, unless Opiant
        responds within sixty (60) days after receipt of said notice with evidence which demonstrates that Opiant (or its Affiliate as
        sublicensee) is using Commercially Reasonable Efforts to Exploit a Product. Aegis’ rights to terminated under this Section
        shall not begin until two (2) years after the Effective Date.

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

	Clinical Trials	Opiant shall furnish to Aegis a copy of the clinical protocol and the related patient informed consent form for any clinical trial study, which involves an Excipient or the Aegis Technology; and Aegis shall be entitled to share such documents with the Aegis insurance carriers to the extent required to comply with its contractual obligations to such entities. Aegis agrees that any personally identifiable information or protected health information, which comes into Aegis’ possession under the license agreement will be protected and acted on in accordance with applicable data protection legislation, such as the Health Insurance Portability and Accountability Act of 1996 as well as all other applicable laws and regulations.”
	 	 
	Excipient Toxicity Studies.	****
	 	 
	Public Filings	The confidentiality obligations of the License and Supply Agreements shall include provisions that in the event a party is required to make public filings or disclosures that will include information or details considered to be confidential by the other party, they parties shall use reasonable best efforts to obtain confidential treatment of such information.
	 	 
	Other Terms: 	The definitive license agreement shall include final terms and customary representations, warranties, covenants and indemnity provisions.

 

     

    
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

    

 

Supply
Agreement Terms and Conditions

 

The Parties will also
use good faith efforts to promptly enter into a Supply Agreement with the following financial terms:

 

Material for Preclinical
Use. Aegis hereby agrees to supply and sell to Opiant
up to one **** grams of GMP Material for Opiant’ use in preclinical studies
at no charge. If additional quantities of GMP Material are needed for preclinical studies, the Parties will negotiate in good faith
pricing for such materials.

 

Material for Clinical and
Commercial Use. Aegis hereby agrees to supply and sell to Opiant
quantities of GMP Material for use by Opiant in its clinical trials and for later
commercial sales, in accordance with the following price schedule:

 

	Grams	 	Order Lead

Time 	 	Cost per

Gram	 	Total	 	Approximate

Doses @****	 	Approximate

Cost per Dose 
	****	 	****	 	****	 	****	 	****	 	****
	****	 	****	 	****	 	****	 	****	 	****
	****	 	****	 	****	 	****	 	****	 	****
	****	 	****	 	****	 	****	 	****	 	****

 

****

		a.	Said prices shall be subject to the Producer Price Index (“PPI”) escalation.

 

		b.	Each Order shall be for a delivery date and a single shipment destination (e.g., a single Order
cannot be for two or more different delivery dates or two or more different shipment destinations). The price per gram is based
upon the number of grams of Material in the Order.

 

		c.	The quantities set forth in the table above are fixed lot sizes. Any request for a quantity other
than as set forth above (e.g., **** grams, or **** grams), shall be subject to good faith negotiations between the parties
as to price and lead time.

 

In the event that Aegis
is unable or unwilling to provide the GMP Material in accordance with FDA GMP guidelines and with the specifications contained
in the Supply Agreement, which specifications shall be negotiated in good faith, Opiant
may at its election obtain the GMP Materials from other third party suppliers or may manufacture the GMP Material itself.Exhibit 10.1

  

 

SEPARATION
AGREEMENT

 

THIS SEPARATION AGREEMENT
(this “Agreement”) is entered into on June 8, 2016 by and between STUART M. PAGE (“Executive”)
and GLORI ENERGY INC., Delaware corporation, and its affiliated companies, corporations, business associations, parents and subsidiaries
(collectively, “Company”). Executive and Company are sometimes referred to herein as a “Party”
and collectively as the “Parties.”

 

WHEREAS, Executive
is an employee of Company;

 

WHEREAS the Parties
entered into an Employment Agreement dated April 14, 2014 (“Employment Agreement”) governing the terms of Executive’s
employment with the Company; and

 

WHEREAS, the Parties
now desire to enter into this Agreement for the purpose of providing for the orderly separation of service of the Executive from
Company.

 

NOW, THEREFORE, in
consideration of the mutual promises contained herein and other good and valuable consideration set forth in this Agreement, the
receipt of which is acknowledged, Executive and Company agree as follows:

 

1.Separation
from Employment; Resignation from Directorships and Officer Positions; Public Disclosure. Employee and Company agree that
Employee’s employment with Company is terminated effective on June 2, 2016 (the “Termination Date”). Employee
hereby resigns from all positions as a director and/or officer of the Company, including any of its affiliates or subsidiaries.
All public release of information relating to Executive’s separation shall be solely made by the Company

 

2.Payment.
Executive shall be paid severance compensation (“Severance”) in accordance with Section 8(a) of the Employment
Agreement as if Executive has resigned for “good reason” as provided therein. The conditions, obligations and covenants
contained in Section 4 and Sections 8 through 27 of the Employment Agreement survive the execution of this Agreement.

 

    	 	- 1 -	 

     

    

 

3.Release.
In consideration of the promises and covenants made in this Agreement, Executive, for himself, his heirs, executors, administrators
and assigns, does hereby RELEASE, ACQUIT AND FOREVER DISCHARGE Company and each of its present and former officers, directors,
shareholders, employees, affiliates, agents, representatives, successors and assigns (all of whom are hereinafter collectively
referred to as “Releasees”) from any and all claims, demands, causes of action and liabilities of any kind or
character, which Executive ever had, now has or may hereafter have against any of Releasees, arising out of any act, omission,
transaction or event occurring prior to or as of the Effective Date, including, without limitation, those related to Executive’s
employment by Company, the termination of his employment, including any rights or benefits thereunder; provided, however, that
Executive shall be entitled to enforce Executive’s rights to the Severance in Section 2 hereof. Without limiting the
generality of the foregoing, it is understood and agreed that this release constitutes and includes a release by Executive of Releasees
from any and all claims, grievances, demands, charges, liabilities, obligations, actions, causes of action, damages, costs, losses
of services, expenses and compensation of any nature whatsoever, whether based on tort, contract or other theory of recovery, on
account of, or in any way growing out of, Executive’s employment with or separation from Company, including, but not limited
to, any claims arising under any of the following statutes: Title VII of the Civil Rights Act of 1964; the Americans with
Disabilities Act of 1990; the Age Discrimination in Employment Act; the Older Workers’ Benefit Protection Act; the Fair Labor
Standards Act; the National Labor Relations Act; the Fair Credit Reporting Act; the Executive Retirement Income Security Act; the
Texas Commission on Human Rights Act; the Texas Payday Law; the Texas Labor Code; the Texas Workers’ Compensation Act; and
any other foreign, state or federal statute or regulation governing the employment relationship or Executive’s rights, or
Company’s obligations, in connection with any of the foregoing. This release also constitutes a release of any claim or cause
of action for the following: invasion of privacy; intentional or negligent infliction of emotional distress; wrongful termination;
promissory estoppel; false imprisonment; defamation; negligent hiring, retention, and/or supervision; negligence or gross negligence;
breach of express or implied contract; breach of any implied covenant; tortious interference with contract or business relations;
misrepresentation; deceptive trade practices; fraud; denial of employment benefits, including, but not limited to, health and retirement
benefits (other than any amounts due under Company’s group medical and dental plan for medical or dental services rendered
to Executive or his dependents prior to the Termination Date and other than rights of Executive concerning Executive’s 401(k)
account maintained under Company’s 401(k) plan) and any other employment-related claims, or for any personal injuries, however
characterized, or by virtue of any facts, acts or events occurring prior to or as of the Effective Date of this Agreement. Notwithstanding
anything to the contrary in this Agreement, this release does not constitute a release or waiver of Executive’s right to
file a charge or participate in an investigation or proceeding conducted by the Equal Employment Opportunity Commission (“EEOC”)
or any other governmental entity with jurisdiction to regulate employment conditions or relations; however, Executive does release
and relinquish any right to receive any money, property or any other thing of value, or any other financial benefit or award, as
a result of any proceeding of any kind or character initiated by the EEOC or any other governmental entity with jurisdiction to
regulate employment conditions or relations.

 

4.Waiver.
Executive hereby acknowledges and agrees that the Release set forth in Section 3 hereof is a general release against Releasees,
and Executive, for himself, his heirs, executors, administrators and assigns, does hereby expressly waive and assume the risk of
any and all claims for damages against any of Releasees that exist as of the date of this Agreement but of which he does not know
or suspect to exist, whether through ignorance, oversight, error, negligence or otherwise, and which, if known, would materially
affect Executive’s decision to enter into this Agreement.

 

5.No Admission;
Savings Clause. Neither the execution of this Agreement, nor the performance of the consideration given for this Agreement,
shall constitute nor be deemed to be an admission of liability on the part of any Party hereto, all of which is expressly denied.
Should any provision of this Agreement be declared or be determined by any court to be illegal or invalid, the validity of the
remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be
deemed not to be a part of this Agreement.

 

    	 	- 2 -	 

     

    

 

6.Acknowledgments.
Executive acknowledges that he has fully informed himself of the terms, contents, conditions and effects of this Agreement and
that, in executing this Agreement, he does not rely and has not relied upon any representation (oral or written) or statement made
by Company or its attorneys, including, but not limited to, any representation or statement with regard to the subject matter,
basis, or effect of this Agreement. Executive further acknowledges the following: that he has been advised to consult with an
attorney prior to executing this Agreement; that he is of sound mind and otherwise competent to execute this Agreement; and that
he is entering into this Agreement knowingly and voluntarily and without any undue influence or pressures. If Executive violates
the terms of any of the provisions of this Agreement or the provisions of the Employment Agreement that survive its execution or
challenges the effectiveness of any release provided herein, Company shall have the right to immediately terminate this Agreement
and Company shall have no obligation to pay any Severance.

 

7.No Assignment.
Executive warrants that he has not conveyed or assigned any interest in the any of the matters or claims being released or waived
in this Agreement.

 

8.Time Period
for Enforceability. Company’s obligation to pay the Severance is contingent upon Executive executing and returning
this Agreement to Company pursuant to the terms of this Agreement.

 

 

[Signature page follows] 

 

    	 	- 3 -	 

     

    

 

EXECUTED AND EFFECTIVE
as of June 8, 2016. 

 

	 	Glori Energy Inc.
	 	 
	 	By 	 
	 	Name: 	 
	 	Title: 	 
	 	 
	 	 
	 	 
	 	Stuart M. Page
	 	 	 
	 	Date: 	 

  

 

Signature Page to Separation Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]